PBPK Modeling: Empowering Drug Development and Precision Dosing in China
ABSTRACT Physiologically based pharmacokinetic (PBPK) modeling, a cornerstone of model‐informed drug development and model‐informed precision dosing, simulates drug disposition in the human body by integrating physiological, biochemical, and physicochemical parameters. While PBPK modeling has advanc...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Online Access: | https://doi.org/10.1002/psp4.70004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849312779985485824 |
|---|---|
| author | Dongsheng Yang Jian Li Wen Yao Mak Aole Zheng Xiao Zhu Qingfeng He Yuzhu Wang Xiaoqiang Xiang |
| author_facet | Dongsheng Yang Jian Li Wen Yao Mak Aole Zheng Xiao Zhu Qingfeng He Yuzhu Wang Xiaoqiang Xiang |
| author_sort | Dongsheng Yang |
| collection | DOAJ |
| description | ABSTRACT Physiologically based pharmacokinetic (PBPK) modeling, a cornerstone of model‐informed drug development and model‐informed precision dosing, simulates drug disposition in the human body by integrating physiological, biochemical, and physicochemical parameters. While PBPK modeling has advanced globally since the 1970s, China's adoption of this technology has followed a distinctive path, characterized by accelerated growth over the past 2 decades. This review provides a comprehensive analysis of China's contributions to PBPK modeling, addressing knowledge gaps in publication trends, application domains, and platform preferences. A systematic literature search yielded 266 original PBPK research articles from PubMed up to August 08, 2024. The analysis revealed that drug disposition and drug–drug interaction studies constitute the largest proportion of PBPK analyses in China. Chinese universities and hospitals emerge as the leading contributors to PBPK research among institutions in China. Although established commercial PBPK platform such as GastroPlus and Simcyp remain popular within the Chinese pharmaceutical industry, open‐source platforms like PK‐Sim are gaining significant traction in PBPK applications across China. This review underscores the transformative potential of PBPK modeling in drug development within China, offering valuable insights into future directions and challenges in the field. |
| format | Article |
| id | doaj-art-fd3f4aeffcea41a2a5ffbd6df8fba4fb |
| institution | Kabale University |
| issn | 2163-8306 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | CPT: Pharmacometrics & Systems Pharmacology |
| spelling | doaj-art-fd3f4aeffcea41a2a5ffbd6df8fba4fb2025-08-20T03:52:57ZengWileyCPT: Pharmacometrics & Systems Pharmacology2163-83062025-05-0114582883910.1002/psp4.70004PBPK Modeling: Empowering Drug Development and Precision Dosing in ChinaDongsheng Yang0Jian Li1Wen Yao Mak2Aole Zheng3Xiao Zhu4Qingfeng He5Yuzhu Wang6Xiaoqiang Xiang7Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy Fudan University Shanghai ChinaCenter for Drug Evaluation, National Medical Products Administration Beijing ChinaDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy Fudan University Shanghai ChinaDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy Fudan University Shanghai ChinaDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy Fudan University Shanghai ChinaDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy Fudan University Shanghai ChinaCenter for Drug Evaluation, National Medical Products Administration Beijing ChinaDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy Fudan University Shanghai ChinaABSTRACT Physiologically based pharmacokinetic (PBPK) modeling, a cornerstone of model‐informed drug development and model‐informed precision dosing, simulates drug disposition in the human body by integrating physiological, biochemical, and physicochemical parameters. While PBPK modeling has advanced globally since the 1970s, China's adoption of this technology has followed a distinctive path, characterized by accelerated growth over the past 2 decades. This review provides a comprehensive analysis of China's contributions to PBPK modeling, addressing knowledge gaps in publication trends, application domains, and platform preferences. A systematic literature search yielded 266 original PBPK research articles from PubMed up to August 08, 2024. The analysis revealed that drug disposition and drug–drug interaction studies constitute the largest proportion of PBPK analyses in China. Chinese universities and hospitals emerge as the leading contributors to PBPK research among institutions in China. Although established commercial PBPK platform such as GastroPlus and Simcyp remain popular within the Chinese pharmaceutical industry, open‐source platforms like PK‐Sim are gaining significant traction in PBPK applications across China. This review underscores the transformative potential of PBPK modeling in drug development within China, offering valuable insights into future directions and challenges in the field.https://doi.org/10.1002/psp4.70004 |
| spellingShingle | Dongsheng Yang Jian Li Wen Yao Mak Aole Zheng Xiao Zhu Qingfeng He Yuzhu Wang Xiaoqiang Xiang PBPK Modeling: Empowering Drug Development and Precision Dosing in China CPT: Pharmacometrics & Systems Pharmacology |
| title | PBPK Modeling: Empowering Drug Development and Precision Dosing in China |
| title_full | PBPK Modeling: Empowering Drug Development and Precision Dosing in China |
| title_fullStr | PBPK Modeling: Empowering Drug Development and Precision Dosing in China |
| title_full_unstemmed | PBPK Modeling: Empowering Drug Development and Precision Dosing in China |
| title_short | PBPK Modeling: Empowering Drug Development and Precision Dosing in China |
| title_sort | pbpk modeling empowering drug development and precision dosing in china |
| url | https://doi.org/10.1002/psp4.70004 |
| work_keys_str_mv | AT dongshengyang pbpkmodelingempoweringdrugdevelopmentandprecisiondosinginchina AT jianli pbpkmodelingempoweringdrugdevelopmentandprecisiondosinginchina AT wenyaomak pbpkmodelingempoweringdrugdevelopmentandprecisiondosinginchina AT aolezheng pbpkmodelingempoweringdrugdevelopmentandprecisiondosinginchina AT xiaozhu pbpkmodelingempoweringdrugdevelopmentandprecisiondosinginchina AT qingfenghe pbpkmodelingempoweringdrugdevelopmentandprecisiondosinginchina AT yuzhuwang pbpkmodelingempoweringdrugdevelopmentandprecisiondosinginchina AT xiaoqiangxiang pbpkmodelingempoweringdrugdevelopmentandprecisiondosinginchina |